Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro

Kwon, Paul S.
Oh, Hanseul
Kwon, Seok Joon
Jin, Weihua
Zhang, Fuming
Fraser, Keith
Hong, Jung Joo
Linhardt, Robert J.
Dordick, Jonathan S.
Thumbnail Image
Other Contributors
Issue Date
Biology , Chemistry and chemical biology , Chemical and biological engineering , Biomedical engineering
Terms of Use
Attribution 3.0 United States
CC BY : this license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. Credit must be given to the authors and the original work must be properly cited.
Full Citation
Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro, P. S. Kwon, H. Oh, S.-J. Kwon, W. Jin, F. Zhang, K. Fraser, J. Hong, R. J. Linhardt, J. S. Dordick, Cell Discovery 6, 50, 2020.
COVID-19, caused by the SARS-CoV-2 virus, has now spread worldwide with catastrophic human and economic impacts and currently has infected over 10 million people and killed over 500,0001. In an effort to mitigate disease symptoms and impede viral spread, efforts in vaccine development and drug discovery are being conducted at a rapid pace2. Recently, we showed that the well-known anticoagulant heparin has exceptional binding affinity to the spike protein (S-protein) of SARS-CoV-23. The S-protein of SARS-CoV-2 bound more tightly to immobilized heparin (KD = ~10−11 M) than the S-proteins of either SARS-CoV (KD = ~10−7 M) or MERS-CoV (KD = ~10-9 M). However, it is not known whether the tight binding of heparin to the SARS-CoV-2 S-protein translates into potent antiviral activity. In the current study, we evaluated the in vitro antiviral properties of heparin and other closely related polysaccharides to assess the relevance of heparin-related GAGs and other sulfated polysaccharides as part of the pharmacopeia of potential therapeutics that target SARS-CoV-2. Vero-CCL81, which expresses both ACE2 and TMPRSS24, were used for viral replication at high titer5 for use in antiviral assays.
Cell Discovery 6, 50
Note : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
The Linhardt Research Labs.
The Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies (CBIS)
The Linhardt Research Labs Online Collection
Rensselaer Polytechnic Institute, Troy, NY
Cell Discovery
A full text version is available in DSpace@RPI
CC BY — Creative Commons Attribution